Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug ...

The drug was discovered by Pfizer, which sought to link up with Merck because it has the current market leading oral treatment, Januvia. Januvia and combo drug Janumet posted a very respectable 4% ...

Merck has already had two drugs picked for the yearly list of drugs subject to price negotiations, with a 79% Medicare price cut set to go into effect for its Januvia in 2026 and price ...